APL, a malignancy driven by PML/RARA
====================================

Leukemias are a type of cancer caused by the malignant proliferation of bone marrow--derived cells that invade the bloodstream, distance organs, and induce loss of normal bone marrow. These dreaded diseases actually represent a wide spectrum ranging from relatively indolent conditions, which rarely shorten survival, to high-malignancy ones for which there are few therapeutic options to date. Leukemias are usually classified as acute or chronic and lymphoid or myeloid, depending on the phenotype of the malignant cell. Leukemias share certain definitive features: (a) deficient formation of blood cells, anemia, and hemorrhages mainly caused by the loss of platelets (thrombopenia) and infections related to myeloid and lymphoid deficiencies; and (b) tumor mass, with high levels of abnormal leukemia cells in the blood, lymphoid organs, or other organs. Some acute leukemias have benefited from treatments with inhibitors of DNA replication, such as DNA cross-linkers, and topoisomerase or nucleotide synthesis inhibitors. These have allowed the overwhelming majority of children with acute lymphoblastic leukemia to be definitively cured. Unfortunately, many of the other acute or chronic leukemias still have a dismal prognosis.

Cancer is linked to the accumulation of genetic or epigenetic events that enable unrestrained proliferation. In leukemias, these events have progressively been discovered, starting with the first chromosomal translocations disclosed in the 1960's up to more recent full genome sequencing or epigenetic cartographies ([@bib68]; [@bib35]). This has resulted in a molecular classification of unprecedented precision. For example, acute myeloid leukemias are all linked by their phenotypic characters but really constitute a mosaic of genetically diverse diseases, each very rare ([@bib72]; [@bib26]). Critically, molecular features are more accurate than morphology at predicting evolution and response to therapy. For example, a given kinase inhibitor induces remission and prolonged survival only in those cases in which that specific kinase is mutated ([@bib98]).

Acute promyelocytic leukemia (APL) is a rare condition (100 new cases/year in France) though extremely malignant because of its very rapid spontaneous evolution and occurrence of sudden hemorrhages mainly caused by coagulation disorders ([@bib45]; [@bib119]). Indeed, in addition to diminished platelet counts, APL cells contain enzymes and proteins that, when liberated in the bloodstream, activate the coagulation cascade ([@bib113]). APL is associated with specific chromosomal translocations that always involve the *retinoic acid* (*RA*) *receptor α* (*RARA*) gene on chromosome 17 to create a variety of X-RARA fusions ([@bib89]). The most common one is the t(15,17) translocation encoding the PML/RARA fusion ([@bib97]; [@bib24], [@bib25]), which is associated with \>98% of APL cases. The second most common translocation t(11,17) encodes PLZF/RARA and is associated clinically with RA-resistant APLs ([@bib11]; [@bib69]). In APLs driven by the t(15,17) translocations, PML/RARA is most often the only driving genetic alteration; epigenetic changes appear limited ([@bib123]; [@bib35]; [@bib73]; [@bib120]). Indeed, full genome sequencing has demonstrated rare and inconsistent additional mutations ([@bib123]). It is most likely that these facilitate disease progression, rather than initiation, as well known for FLT3 activation or Myc amplification ([@bib104]; [@bib53]). It is thus the view of the authors that APL represents a monogenic cancer primarily, if not exclusively, driven by PML/RARA. In that respect, PML/RARA ([Fig. 1 a](#fig1){ref-type="fig"}) initiates a typical APL when expressed in transgenic mice ([@bib9]; [@bib39]). In that setting, APL development requires a few months, and penetrance is not complete. The latter may either suggest that, in that setting, genetic/epigenetic changes besides PML/RARA expression are required for progression to full transformation or that the cells of origin in mice somehow differ from those in humans. Another possibility is that additional genetic or epigenetic changes are required for PML/RARA posttranslational modifications that significantly affect PML/RARA function in vivo ([@bib134]; [@bib83]).

![**PML/RARA, RA, arsenic, and APL.** (a) The PML/RARA fusion protein with the main functional domains of PML and RARA. Note that RA targets the RARA moiety, and arsenic targets the PML moiety, both leading to PML/RARA degradation. Black arrowheads denote the different fusion points. DNA, DNA-binding domain; AF2, activating function 2. (b) RA treatment in vivo elicits the differentiation of leukemia cells (reproduced from [@bib133] with permission from Nature Publishing Group). Bars, 5 µm. (c) Current models of RA or arsenic action on transcriptional control and differentiation through gene activation (top) or derepression via degradation (bottom).](JCB_201112044_Fig1){#fig1}

RARA is an RA nuclear receptor that acts as a hormone-dependent transcriptional switch. RA has been implicated in many biological responses, notably differentiation of multiple progenitors as well as myeloid cells. PML is the organizer of nuclear domains known as PML nuclear bodies (NBs), as detailed in the next section. Like many other malignancy-associated fusion proteins, PML/RARA has a dual dominant-negative activity on signaling by each of its constitutive partners ([@bib78]). Accordingly, PML/RARA is a potent repressor of nuclear hormone receptor signaling, but it also disrupts PML NBs.

Two therapeutic agents, RA and arsenic trioxide, induce differentiation of promyelocytes in vivo and clinical remission of APL patients ([Fig. 1 b](#fig1){ref-type="fig"}). However, although RA induces only transient remissions ([@bib119]), arsenic by itself cures ≤70% of APL patients ([@bib75]; [@bib36]). Reactivation of PML/RARA-repressed transcription by RA was logically proposed to explain the induction of differentiation and clearance of APL, exemplifying a remarkable model of both differentiation- and transcription-targeted cancer therapy ([Fig. 1 c](#fig1){ref-type="fig"}). Arsenic also induces some differentiation, albeit delayed relative to the effect of RA. Clearly, the transcriptional reactivation model cannot account for the arsenic effect, which does not significantly alter nuclear receptor signaling ([@bib1]). As we discuss later, both RA and arsenic degrade PML/RARA ([Fig. 1 a](#fig1){ref-type="fig"} and see [Fig. 3](#fig3){ref-type="fig"}). Thus, abrogation of PML/RARA-mediated repression was proposed to explain arsenic-triggered differentiation ([Fig. 1 c](#fig1){ref-type="fig"}). Recent genetic and pharmacological evidence have demonstrated that RA-induced differentiation and clearance of APL may be uncoupled ([@bib83]; [@bib1]). For example, in PLZF/RARA-driven APLs (in which PLZF alterations likely substitute for the absence of PML disruption), leukemic cells differentiate upon exposure to RA but fail to clear, suggesting that in PML/RARA-driven APL, restoring PML NBs may contribute to APL regression. Preclinical studies performed in several APL murine models have demonstrated that RA and arsenic dramatically synergize for clearing APL ([@bib60]; [@bib95]). This has led to clinical trials (frontline RA/arsenic combination) that have resulted in the cure of virtually all patients ([@bib101]; [@bib32]; [@bib47]; [@bib112]; [@bib23]). Moreover, a recent clinical meta-analysis has demonstrated that the combination of arsenic and RA in APL patients increased the complete remission rates, shortened the time required to reach remission, and also increased the disease-free survival, perfectly in line with the findings of mouse models ([@bib62]; [@bib117]). Hence, APL is the first example of an oncogene-targeted cancer cure ([@bib91]; [@bib118]; [@bib112]; [@bib23]).

APL research revives mysterious nuclear organelles
==================================================

The first description of NBs as electron-dense shells with electron-light cores was made in spontaneous tumors of *Papilloma* virus--infected rabbits ([@bib22]). These domains were later identified by immunofluorescence analysis using autoimmune sera from patients with primary biliary cirrhosis ([@bib3]). At the time that the first NB-associated autoantigen, SP100, was cloned ([@bib111]), a monoclonal antibody against crude nuclear matrix was shown to recognize nuclear domains also containing SP100 ([@bib108]). This monoclonal antibody actually recognizes PML ([@bib29]; [@bib57]). In electron microscopy, PML constitutes the outer shell of the sphere ([Fig. 2 a](#fig2){ref-type="fig"}, left) and, as formally demonstrated using *pml^−/−^* cells, is the organizer of these domains, into which it recruits SP100 and multiple other proteins ([@bib49]; [@bib61]; [@bib59]).

![**PML and NBs.** (a) PML NBs in normal and APL cells. From left to right: (normal cells) immunofluorescence and electron microscopy views in CHO cells stably expressing PML. (left) PML is both diffusely distributed in the nucleoplasm and aggregated in NBs. The red arrow points to an individual body, analyzed by electron microscopy. Bar, 1 µm. (right) anti-PML antibodies, labeled with gold particles, show PML distribution in the electron-dense NB shell. Bar, 0.5 µm. (APL cells) NB disruption into micropunctuations by PML/RARA expression (left) and reformation upon arsenic treatment (right). (normal cells) Arsenic controls NB aggregation in non-APL cells. CHO cells stably expressing PML were treated (right) or not treated (left) with 1 µM As~2~O~3~ for 1 h. Note the disappearance of the diffuse nuclear staining and increased size of NBs. (b) PML structure and SUMO-induced modifications. Interactions of partner proteins with SUMO--SIM are shown as dotted lines. PML primarily interacts with its partners through K160 sumoylation (1); NB association of sumoylated partners is secured by subsequent SIM--SUMO reciprocal interactions between partners and possibly PML SIM (2). (c) PML cross-linking by disulfide bounds underlies formation of the matrix-associated shell, and polarized SUMO--SIM interactions recruit partner proteins within NBs. PML multimers recruit Ubc9, leading to sumoylation of PML and possibly its partners. S, sulfur. (d) PML targeting to the insoluble nuclear matrix (NM) after arsenic exposure. Reproduced from [@bib61]. Molecular masses are given in kilodaltons. N, nucleoplasm.](JCB_201112044R_Fig2){#fig2}

That PML/RARA expression disrupts PML NBs ([Fig. 2 a](#fig2){ref-type="fig"}, middle; [@bib18]) indicated that the (elusive) function of NBs might be blocked by PML/RARA, possibly contributing to leukemogenesis. Indeed, this proposal was later substantiated by establishing formal links between PML NBs and self-renewal of normal or cancer stem cells ([@bib50]; [@bib94]). Strikingly, treatment with RA allowed reformation of normal NBs ([@bib18]; [@bib29]; [@bib57]; [@bib122]), which was later explained by the fact that PML/RARA was degraded under the effect of RA ([Fig. 1 c](#fig1){ref-type="fig"}; [@bib93]; [@bib131]) and that PML proteins produced from the nonrearranged *PML* allele reformed PML NBs. Thus, the NB status mirrored cell malignancy, suggesting that NB reformation may contribute to the RA therapeutic effect. These results have drawn a considerable amount of interest in these domains.

Arsenic also elicits PML/RARA degradation and NB reformation ([Fig. 2 a](#fig2){ref-type="fig"}, middle; [@bib130]) but acts via the PML rather than the RARA moiety of PML/RARA ([Fig. 1 a](#fig1){ref-type="fig"}). Indeed, similar to RA, which degrades RARA, arsenic degrades normal PML and, thus, PML/RARA oncoprotein ([Fig. 3](#fig3){ref-type="fig"}). This unexpected convergence between two clinically active agents, discovered by chance, strongly reinforced the idea that PML/RARA degradation, and hence PML NB reformation, contributed to clinical remissions ([@bib91]; [@bib23]; [@bib2]). PML is normally distributed between NBs and the rest of the nucleoplasm ([Fig. 2 a](#fig2){ref-type="fig"}, right). Although PML is more readily detectable by immunofluorescence when associated with NBs, its diffuse, nonmatrix-associated fraction is often actually the most abundant ([Fig. 2 d](#fig2){ref-type="fig"}). A pioneering study had demonstrated that arsenic has the unique property of changing this equilibrium by promoting PML targeting onto NBs and nuclear matrix association, before the onset of degradation ([Fig. 2](#fig2){ref-type="fig"} a \[right\] and d; [@bib130]). Thus, arsenic became an invaluable tool to approach both APL pathogenesis and NB assembly ([@bib133]).

![**PML or PML/RARA degradation by arsenic trioxide.** Arsenic enhances multi- and/or polysumoylation by SUMO1/2/3 on K65 and K160, but not K490, as demonstrated by Western blotting after short treatment of CHO cells stably expressing PML (top, middle lane); PML proteins are degraded after longer exposure to arsenic (top, right lane). The ubiquitin E3 ligase RFN4 comprises four SIMs and is thus recruited onto dimerized, mesh-associated, hypersumoylated PML to induce its polyubiquitination (poly-Ub). PML is finally degraded by the proteasome machinery, which is also recruited onto NBs. The yellow arrow depicts the events occurring in the first hour after arsenic, and the green one shows subsequent degradation (corresponding to polyubiquitination).](JCB_201112044_Fig3){#fig3}

PML encages other proteins.
---------------------------

PML forms a shell surrounding the core of NBs and, thus, creates a partition within the nucleoplasm ([@bib4]; [@bib59]; [@bib66]). PML NBs have the ability to recruit an ever-growing number of proteins, the most extensively studied of which being SP100 and DAXX. Only few partners (such as SP100) are constantly NB associated, whereas most are massively recruited in response to stress. These multiple partner proteins, which all accumulate within the core ([@bib66]), have nothing in common except that they all can undergo sumoylation. Only the PML shell, but not its binding partners, is associated with the nuclear matrix (unpublished data). Consistent with this association, NBs are relatively stable, with its binding partners moving to and from the nucleoplasm ([@bib30]; [@bib121]). PML is generally considered to be the sole organizer of NBs by a seeding effect. However, a recent study has proposed that SP100 is also important in PML NB formation ([@bib85]). PML and SP100 appear to stabilize each other (unpublished data; [@bib84]), so that it is possible that absence of SP100 results in very low levels of PML that preclude self-association into NBs. Similarly, the fact that some NB-associated proteins, such as EIF4e, can form speckles in the absence of PML has led to the proposal that EIF4e domains may preexist and nucleate PML NBs ([@bib15]). Because PML bodies are primarily defined by the presence of PML, the existence of speckled distribution of other NB-associated proteins (such as EIF4e, Sp100, and PLZF) in PML absence likely denotes the ability of partners to self-aggregate and thus nucleate distinct and specific domains.

Initially, PML NBs were not reported to harbor DNA or RNA within their core ([@bib108]; [@bib8]). Yet, nascent messenger RNAs have been found within some NBs ([@bib65]). This may reflect different NB makeups according to cell types and/or that NBs may represent a somehow heterogeneous group of domains. Like most other nuclear domains, NBs localize within the interchromatin space, in between chromosomal territories ([@bib74]). Statistical associations between NBs and transcription sites suggest that neighboring chromatin plays a role in NB localization within the nucleus ([@bib115]; [@bib102]; [@bib31]). Curiously, association between NBs and specific loci was found for both activated and repressed genes.

Several types of PML bodies.
----------------------------

PML is expressed as splice variants with the same N terminus, but distinct C terminus, sequences ([@bib52]). PML-I has a nuclear export signal, a nucleolar-targeting signal (primarily active in senescent cells), and an exonuclease III domain of unknown function ([@bib17]). Although PML-I appears to be the most strongly expressed in nontransformed cells or normal tissues, this has not been extensively investigated in primary cells. All isoforms interact via their coiled coil and hence colocalize in NBs. Yet, when expressed individually in *pml^−/−^* cells, isoforms yield NB formation but with distinct morphologies ([@bib16]), suggesting that their C termini interact with specific cellular components. Thus, each isoform may have particular functions.

Apart from isoform expression, the cellular context appears to exert a great effect. For example, PML aggregates in threads in Ras-transformed cells ([@bib108]), whereas human embryonic stem cells exhibit short threads that seem to join to unidentified structures ([@bib10]). Similarly, PML association with different compartments can occur in response to a variety of stresses, such as telomere shortening, DNA damage, aggregation of misfolded proteins, deregulation of ribosome biogenesis, senescence, and proteasome inhibition ([@bib54]; [@bib77]; [@bib5]; [@bib17]). In contrast to classical NBs, those generated by alternative lengthening of telomeres or in response to DNA damage contain specific DNA sequences ([@bib28]; [@bib13]). Furthermore, significant proximity between NBs and the genome of incoming viruses has been noted, often resulting in viral transcriptional silencing ([@bib33]).

The SUMO connection
===================

SUMOs are ubiquitin-like peptides that conjugate to lysine (K) residues of many proteins, changing their subcellular localization or ability to interact with their partners ([@bib43]). SUMO can also bind to a short hydrophobic sequence, the SUMO-interacting motif (SIM). PML can be sumoylated on three different K residues and contains a SIM domain ([Fig. 2 b](#fig2){ref-type="fig"}; [@bib7]; [@bib80]; [@bib61]). Nuclear matrix-- and NB-associated PML is massively sumoylated ([@bib51]), and sumoylation on the critical K160 residue ([Fig. 2 b](#fig2){ref-type="fig"}) is the key factor that controls recruitment of most partner proteins ([@bib49]; [@bib61]). It is currently not known whether conjugation of K160 by the SUMO1 or SUMO2 isoforms recruits similar or different partners.

Conversely, most PML-binding proteins contain a SIM, which is essential for targeting onto NBs ([@bib70]; [@bib12]). Thus, the interaction initiating partner recruitment into NBs is likely to occur between PML-bound SUMO and the partner's SIM ([Fig. 2 b](#fig2){ref-type="fig"}). Importantly, a SIM is also required for sumoylation of most, if not all, NB-associated proteins analyzed to date ([@bib70]; [@bib12]). This may reflect the role of SIMs in anchoring SUMO-conjugating enzyme UBC9 onto its targets ([@bib79]), but it also suggests that sumoylation of partners might occur in situ within NBs, supporting then their transient sequestration through multiple intermolecular SUMO--SIM associations within the NB core ([Fig. 2 c](#fig2){ref-type="fig"} and [Fig. 4](#fig4){ref-type="fig"}). Although PML's SIM is not required for partner recruitment into NBs (unpublished data), interaction of sumoylated partners with PML's own SIM may further contribute to their stable association within NBs.

![**PML NB partners and NB-triggered biological responses.** (a) PML oxidation elicits PML NB formation. Enzymes, such as SUMO E2 Ubc9, SUMO E3 SMC5/6 subunits, ubiquitin E3 RNF4, the acetyltransferase CBP, or the kinase HIPK2, are recruited onto NBs. Concentrating enzymes and their substrates supports posttranslational modifications of partner proteins, such as SP100, the structural maintenance or chromosome (SMC) complex involved in alternative lengthening telomeres, DAXX, or p53. These modifications affect activity and stability of PML partners and/or lead to their sequestration within NBs, converging into quiescence (stem cells) or a senescence program. (b) Proposed links between PML NB reformation and APL response to treatment. PML/RARA disrupts NBs, which could be reflected in aberrant self-renewal. RA or arsenic, by degrading PML/RARA, allows reformation of PML NBs, as do reactive oxygen species (ROS) and possibly anthracyclins. (c) In therapy-resistant APLs, as a result of mutations in PML/RARA, therapies fail to restore NBs.](JCB_201112044R_Fig4){#fig4}

Could similar SUMO--SIM interactions also account for PML multimerization and NB assembly as previously suggested ([@bib80]; [@bib100])? This commonly accepted proposal has limitations because (a) SUMO--SIM interactions are weak and unlikely to confer matrix properties to PML, and (b) PML mutants lacking SIM still yield NBs (unpublished data), as do PML mutants that cannot be sumoylated ([@bib61]). Recent studies have demonstrated that nuclear matrix--associated PML is primarily constituted of disulfide-bound PML homodimers ([Fig. 2 c](#fig2){ref-type="fig"}; [@bib51]; [@bib127]), providing a plausible biochemical basis for such association. Nevertheless, specific bodies, such as those encapsulating telomeres, nucleoli, aggregated misfolded proteins, or sites of DNA repair, may result from PML recruitment onto preexisting aggregates of sumoylated partner proteins, notably those bound to telomeres or DNA breaks ([@bib90]; [@bib13]). In these specific cases, partner--SUMO and PML--SIM interactions may be critical to nucleate NB assembly.

PML oxidation and arsenic-induced PML/RARA degradation
======================================================

Disulfide-mediated PML homodimerization was discovered in studies aimed at understanding the biochemical basis of arsenic-induced PML transfer to the nuclear matrix ([Fig. 2 d](#fig2){ref-type="fig"}). Arsenic induces oxidative stress ([@bib55]), which results in PML cross-linking by disulfide bonds, leading to matrix association and NB formation ([@bib51]). In addition, a PML cysteine directly binds to arsenic ([@bib51]; [@bib127]). These findings indicate that PML multimerization and aggregation of the mesh forming the outer shell of NBs is primary achieved through the combination of noncovalent (coiled coil) and covalent (disulfide) interactions ([Fig. 2 c](#fig2){ref-type="fig"}). Interestingly, the role of long coiled coils has been established for other matrix proteins, such as lamins, and the nuclear matrix comprises large numbers of disulfide-bound proteins ([@bib109]; [@bib88]). Control of PML aggregation by redox stress likely explains why, in vivo, NBs have repeatedly been associated with inflammation or neoplastic transformation ([@bib58]). Although these models derive from few studies and thus await independent confirmation, some previous studies had demonstrated that the protein recognized by 5E10 (later shown to be PML) could undergo oxidation within the nuclear matrix ([@bib109]), whereas cysteine starvation (and hence oxidative stress) profoundly affects NB biogenesis ([@bib54]).

Nuclear matrix aggregated, disulfide-bound PML is massively sumoylated ([@bib51]). PML can directly bind the SUMO E2 ligase UBC9 via its RING finger. Thus, PML multimerization could allow hypersumoylation in trans of the aggregated PML mesh ([Fig. 2 c](#fig2){ref-type="fig"}), although some PML sumoylation may also occur before targeting to the matrix ([@bib51]). Direct arsenic binding onto PML was also proposed to support UBC9 anchoring, which facilitates PML sumoylation ([@bib127]), whereas inhibition of SUMO proteases may further enhance PML hypersumoylation.

Arsenic induces both PML and PML/RARA degradation. The molecular mechanisms involved have been extensively reviewed elsewhere ([@bib23]; [@bib64]). In the same manner as for partner protein recruitment, arsenic-elicited PML degradation is initiated by sumoylation of K160 ([Fig. 3](#fig3){ref-type="fig"}; [@bib61]). The arsenic-induced, disulfide-linked PML hypersumoylated mesh recruits then a SUMO-dependent ubiquitin ligase, RNF4 ([@bib42]), which enforces PML polyubiquitination. This allows recruitment of the proteasome and, ultimately, PML degradation ([@bib63]; [@bib114]). The original evidence for this SUMO-initiated degradation pathway ([@bib61]) was largely ignored because, at the time, SUMOs were believed to compete with and inhibit ubiquitin-initiated proteolysis ([@bib21]).

Relevance of this model to clinical APL response to arsenic is supported by several recent observations. Cells transformed by PML/RARA point mutants, which cannot bind arsenic and therefore fail to degrade, do not undergo arsenic-induced differentiation ex vivo ([@bib51]). Vitamin E derivatives that poison mitochondria and induce reactive oxygen species elicit long-term remissions in murine models of APL ([@bib27]). Similarly, nonarsenic oxidants, such as Paraquat, elicit both NB reformation and APL regression in PML/RARA-driven disease only ([@bib51]). Finally, mutations adjacent to the arsenic binding site in PML/RARA were found in two arsenic-resistant patients ([Fig. 4 c](#fig4){ref-type="fig"}; [@bib37]). In retrospect, reactive oxygen species--induced PML/RARA degradation may explain why anthracyclins, which induce massive production of reactive oxygen species, show some efficacy in APL, alone or in combination with RA ([@bib119]).

PML NBs as general stress sensors
=================================

*PML* expression is dramatically enhanced by interferons, p53, and Wingless integration site signaling ([@bib105]: [@bib103]; [@bib20]). Such transcriptional control must be taken into account when trying to solve the PML puzzle and may be part of a general response to stress ([@bib19]). Beside oxidative stress, other signals may be important for NB morphogenesis, at least in part through PML posttranslational modifications (such as phosphorylation, acetylation, and sumoylation). PML can be phosphorylated by ATRX, HIPK2, CHK2, or CK2. CHK2 phosphorylation is required for apoptosis ([@bib124]), and CK2-mediated phosphorylation of PML SIM domain results in PML degradation ([@bib99]). PML SIM phosphorylation may modulate its affinity for SUMO-conjugated RNF4, as reported for other SUMO--SIM couples ([@bib44]; [@bib106]).

What happens downstream of stress-induced PML NB formation remains debated. Arsenic regulates partitioning of repressors, such as DAXX, between chromatin and NBs ([@bib67]; [@bib70]). Thus, PML oxidation may indirectly regulate transcription of DAXX-bound promoters ([Fig. 4 a](#fig4){ref-type="fig"}). PML may also promote sumoylation of partner proteins. In this respect, PML and sumoylation of DAXX are required for interferon-triggered B cell apoptosis ([@bib81]). Sumoylation of partners within NBs could facilitate their subsequent phosphorylation or acetylation by locally concentrating sumoylated enzymes and substrates, as suggested for p53 activation by the HIPK2 kinase and Creb-binding protein (CBP) acetylase ([Fig. 4 a](#fig4){ref-type="fig"}; [@bib110]). Finally, it is possible that, in the same manner as PML, some partner proteins are ultimately degraded within NBs through the RNF4 pathway ([Fig. 4 a](#fig4){ref-type="fig"}). Collectively, NBs appear as domains assembled by oxidative stress and sumoylation, whose assembly controls stress-induced posttranslational modifications of a wide variety of proteins.

The mysterious senescence connection
====================================

PML overexpression induces cell senescence, growth arrest, or apoptosis ([@bib92]). Conversely, *pml^−/−^* cells resist several apoptotic signals and do not undergo senescence in response to Ras signaling ([@bib34]; [@bib87]). PML is clearly required for some activities of p53 ([@bib38]), but the exact mechanisms involved remain debated. PML has been proposed to facilitate p53 acetylation or phosphorylation by CBP or HIPK2, respectively ([@bib87]; [@bib46]), or to sequester MDM2 ([Fig. 4 a](#fig4){ref-type="fig"}; [@bib5]). Interestingly, although all PML splice variants recruit p53 into NBs, only one of them activates p53 and induces senescence ([@bib6]). Yet, p53 is not the sole actor in PML-triggered senescence. Indeed, PML can also interact with the E2F--retinoblastoma pathway, although mechanistic details remain imperfectly understood ([@bib116]). Finally, PML could play a role in the formation of senescence-associated heterochromatin foci, in which heterochromatin proteins (such as HIRA, HP1, and ASF1) transit via NBs before establishment of heterochromatin foci and senescence ([@bib126]; [@bib125]). In any case, this prosenescent role of PML NBs likely explains why they are frequently observed in early tumor cells and much less as tumors progress ([@bib58]; [@bib40]). For example, in advanced lung cancers, CK2 activation was proposed to account for PML loss, a process believed to counteract PML-mediated growth suppression and hence favor tumor progression ([@bib99]).

Reintegrating PML NBs in APL pathogenesis and response to therapy
=================================================================

The now well-established role of PML in cell senescence and modulation of p53 signaling sheds new light on the involvement of NB disruption by PML/RARA in APL pathogenesis. Several studies have found that PML/RARA expression impedes p53 signaling and blocks the effects of p53 activation on cell death or clonogenic growth ([@bib87]; [@bib48]). Recent studies have unraveled p53 key function in controlling "stemness" or self-renewal ([@bib129]; [@bib14]; [@bib128]), mediated in part by enforcing G0 arrest of stem cells ([@bib71]). Importantly, very similar findings were reported for PML ([@bib50]; [@bib94]). It is therefore possible that PML directly contributes to this specific function of p53. Thus, NB disruption by PML/RARA could foster proliferation and aberrant stem cell self-renewal. In this respect, it is of note that attempts to induce APL in vivo through deregulation of RARA signaling have been largely unsuccessful ([@bib56]; [@bib76]; [@bib107]). Importantly, recent studies have demonstrated that the PML coiled-coil dimerization domain is essential for RARA to induce APL, most likely because it allows disruption of PML NBs ([@bib86]).

The PML relationship with cell senescence and stem cell self-renewal is critical, not only for understanding APL initiation but also the basis of the response to therapy ([Fig. 4 b](#fig4){ref-type="fig"}). Indeed, NB reformation in response to RA or arsenic treatments tightly correlates with this response ([@bib18]; [@bib130]). Thus, NB reformation could precipitate apoptosis or senescence ([Fig. 4 b](#fig4){ref-type="fig"}). In fact, the exquisite treatment response is highly specific to *PML/RARA* (vs. *PLZF/RARA*)-driven disease ([@bib83]), suggesting that NB reformation upon treatment may be a critical determinant of long-term response. In this respect, some differences in the ex vivo sensitivity to RA of murine PML/RARA APLs generated on a *pml^−/−^* background have been reported ([@bib96]), a mutation in the nonrearranged PML gene was observed in a treatment-resistant patient ([@bib41]), and recent data are consistent with an important role of NB reformation in APL eradication in vivo (unpublished data). Collectively, NB reformation upon PML/RARA degradation may be a critical determinant of APL responsiveness to therapy.

Conclusions
===========

Over the past 20 yr, APL has not only been a clinical success story but also incredibly productive for basic science, providing an inspiring example of translational research. The two active drugs were identified largely by chance and shown to represent targeted therapies a posteriori ([@bib91]; [@bib132]; [@bib64]). Modeling APL pathogenesis and basis for treatment response in the mouse allowed an unprecedented molecular and cellular understanding of this malignancy ([@bib62]; [@bib82]). Finally, the APL model highlighted the importance of proteolysis and provided the proof of concept that this could be manipulated for therapeutic purposes ([@bib2]).

This review specifically highlighted the rising importance of the role played by PML and NBs in APL pathogenesis and therapy. Some of the most decisive insights into NBs biogenesis were derived from the analysis of arsenic action in APL, illustrating the power of chemical biology. The role of reactive oxygen species in mediating PML multimerization and NB biogenesis unravels a striking link between a subcellular domain and a physicochemical parameter, suggesting that PML may act as a redox sensor, a proposal consistent with resistance of *pml^−/−^* mice to multiple stress signals.
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